Mission Therapeutics Ltd

MISSION Therapeutics was founded in 2011 by a team of scientists including Professor Steve Jackson FRS, Dr Niall Martin, Dr Xavier Jacq and Dr Keith Menear, along with founding institutes Cancer Research Technology and Cambridge University. The company’s activities build on the research of Professor Jackson, who holds the Frederick James Quick Chair of Biology at the University of Cambridge and is Head of Cancer Research UK Laboratories at The Gurdon Institute in Cambridge and exploit the new and exciting research emerging on the ubiquitin pathways that control cellular responses to DNA damage.

The Company is building a broad platform of technologies for the discovery and further development of first-in-class modulators of ubiquitin pathway enzymes involved in cancer and other diseases. The company is developing drugs to inhibit the proliferation of tumour cells, building on its scientists’ experience in exploiting the concept of synthetic lethality, now an established and powerful mechanism to selectively kill tumour cells.